CoChat
Sign Up
Cited by 400Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatmentsCerebrospinal fluid and hydrocephalus

The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.

Cerebrospinal fluid analysis detects cerebral amyloid-β accumulation earlier than positron emission tomography

Open access
Palmqvist, Sebastian, Mattsson, Niklas, Hansson, Oskar, for the Alzheimer’s Disease Neuroimaging Initiative·2016·Brain
DOI 10.1093/brain/aww015PMC PMC4806222
Open this paper in CoChat — free account

Abstract

See Rabinovici (doi: 10.1093/brain/aww025 ) for a scientific commentary on this article. Cerebral accumulation of amyloid-β is thought to be the starting mechanism in Alzheimer’s disease. Amyloid-β can be detected by analysis of cerebrospinal fluid amyloid-β 42 or amyloid positron emission tomography, but it is unknown if any of the methods can identify an abnormal amyloid accumulation prior to the other. Our aim was to determine whether cerebrospinal fluid amyloid-β 42 change before amyloid PET during preclinical stages of Alzheimer’s disease. We included 437 non-demented subjects from the prospective, longitudinal Alzheimer’s Disease Neuroimaging Initiative (ADNI) study. All underwent 18 F-florbetapir positron emission tomography and cerebrospinal fluid amyloid-β 42 analysis at baseline and at least one additional positron emission tomography after a mean follow-up of 2.1 years (range 1.1–4.4 years). Group classifications were based on normal and abnormal cerebrospinal fluid and positron emission tomography results at baseline. We found that cases with isolated abnormal cerebrospinal fluid amyloid-β and normal positron emission tomography at baseline accumulated amyloid with a mean rate of 1.2%/year, which was similar to the rate in cases with both abnormal cerebrospinal fluid and positron emission tomography (1.2%/year, P = 0.86). The mean accumulation rate of those with isolated abnormal cerebrospinal fluid was more than three times that of those with both normal cerebrospinal fluid and positron emission tomography (0.35%/year, P = 0.018). The group differences were similar when analysing yearly change in standardized uptake value ratio of florbetapir instead of percentage change. Those with both abnormal cerebrospinal fluid and positron emission tomography deteriorated more in memory and hippocampal volume compared with the other groups ( P < 0.001), indicating that they were closer to Alzheimer’s disease dementia. The results were replicated after adjustments of different factors and when using different cut-offs for amyloid-β abnormality including a positron emission tomography classification based on the florbetapir uptake in regions where the initial amyloid-β accumulation occurs in Alzheimer’s disease. This is the first study to show that individuals who have abnormal cerebrospinal amyloid-β 42 but normal amyloid-β positron emission tomography have an increased cortical amyloid-β accumulation rate similar to those with both abnormal cerebrospinal fluid and positron emission tomography and higher rate than subjects where both modalities are normal. The results indicate that cerebrospinal fluid amyloid-β 42 becomes abnormal in the earliest stages of Alzheimer’s disease, before amyloid positron emission tomography and before neurodegeneration starts. See Rabinovici (doi: 10.1093/brain/aww025 ) for a scientific commentary on this article. The success of disease-modifying therapies in Alzheimer’s disease may depend on detecting the earliest signs of abnormal amyloid-β load. Palmqvist et al . show that CSF amyloid-β 42 becomes abnormal before amyloid PET and before neurodegeneration onset in preclinical Alzheimer’s disease. This may have implications for risk factor interventions and future therapies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/brain/aww015

Cites

59 of 59 references verified0 citation errors · 0 not checkable

Statistics

Figures

Graphical abstract See Rabinovici (doi: 10.1093/brain/aww025 ) for a scientific commentary on this article. The success of disease-modifying therapies in Alzheimer’s disease may depend on detecting the earliest signs of abnormal amyloid-β load. Palmqvist et al . show that CSF amyloid-β 42 becomes abnormal before amyloid PET and before neurodegeneration onset in preclinical Alzheimer’s disease. This may have implications for risk factor interventions and future therapies.
Graphical abstract See Rabinovici (doi: 10.1093/brain/aww025 ) for a scientific commentary on this article. The success of disease-modifying therapies in Alzheimer’s disease may depend on detecting the earliest signs of abnormal amyloid-β load. Palmqvist et al . show that CSF amyloid-β 42 becomes abnormal before amyloid PET and before neurodegeneration onset in preclinical Alzheimer’s disease. This may have implications for risk factor interventions and future therapies.CC BY-NC · PubMed Central
Figure 1 CSF amyloid-β42 levels versus global amyloid PET SUVR relative to the composite region . Solid lines represent the predefined thresholds for CSF amyloid-β 42 (<192 ng/l) and florbetapir PET (>0.79 SUVR). Dashed lines represent a ± 5% interval from the thresholds, which was used in the final classification to exclude borderlines cases. Aβ42 = amyloid-β 42 .
Figure 1 CSF amyloid-β42 levels versus global amyloid PET SUVR relative to the composite region . Solid lines represent the predefined thresholds for CSF amyloid-β 42 (<192 ng/l) and florbetapir PET (>0.79 SUVR). Dashed lines represent a ± 5% interval from the thresholds, which was used in the final classification to exclude borderlines cases. Aβ42 = amyloid-β 42 .CC BY-NC · PubMed Central
Figure 2 Boxplots of the amyloid-β accumulation rate (% SUVR change/year) for the different groups. Group comparisons were analysed with Mann-Whitney. There were no CSF–/PET+ individuals in A and only one in B and C . Therefore, this group is not shown. ( A ) Amyloid-β accumulation rate in the global neocortical region. Group classifications were based on the a priori cut-offs for amyloid-β 42 (CSF+<182.4 ng/l, CSF– >201.6 ng/l) and the global neocortical amyloid-β SUVR relative a composite reference region (PET+>0.8295, PET − <0.7505). ( B ) Amyloid-β accumulation rate in the global neocortical region using a PET classification (+/–) based on abnormal/normal amyloid-β in brain regions affected in early amyloid-β deposition (the medial and lateral orbitofrontal cortex and the frontal pole; ‘the early amyloid-β region’). Cut-offs were established with mixture modelling (PET+>0.8579 SUVR, PET– <0.7762 SUVR). The CSF classification was the same as in ( A ). ( C ) Amyloid-β accumulation rate in the ‘early amyloid-β region’ using the same CSF/PET classification as in ( B ). Aβ = amyloid-β.
Figure 2 Boxplots of the amyloid-β accumulation rate (% SUVR change/year) for the different groups. Group comparisons were analysed with Mann-Whitney. There were no CSF–/PET+ individuals in A and only one in B and C . Therefore, this group is not shown. ( A ) Amyloid-β accumulation rate in the global neocortical region. Group classifications were based on the a priori cut-offs for amyloid-β 42 (CSF+<182.4 ng/l, CSF– >201.6 ng/l) and the global neocortical amyloid-β SUVR relative a composite reference region (PET+>0.8295, PET − <0.7505). ( B ) Amyloid-β accumulation rate in the global neocortical region using a PET classification (+/–) based on abnormal/normal amyloid-β in brain regions affected in early amyloid-β deposition (the medial and lateral orbitofrontal cortex and the frontal pole; ‘the early amyloid-β region’). Cut-offs were established with mixture modelling (PET+>0.8579 SUVR, PET– <0.7762 SUVR). The CSF classification was the same as in ( A ). ( C ) Amyloid-β accumulation rate in the ‘early amyloid-β region’ using the same CSF/PET classification as in ( B ). Aβ = amyloid-β.CC BY-NC · PubMed Central
Figure 3 The annual rate of amyloid-β accumulation (%) as a function of CSF amyloid-β 42 levels in PET− and PET+ individuals. The local regression line was fitted using the partial least square criterion (‘LOESS’) and illustrates the increase in accumulation rate with decreasing amyloid-β 42 levels as seen in CSF+/PET+ subjects and at lower amyloid-β 42 levels in CSF−/PET− subjects ( A ). The gap between CSF−/PET− and CSF+/PET− is caused by the exclusion of borderline cases. In B , the local regression line shows an accumulation rate that has plateaued and does not increase with decreasing CSF amyloid-β 42 levels.
Figure 3 The annual rate of amyloid-β accumulation (%) as a function of CSF amyloid-β 42 levels in PET− and PET+ individuals. The local regression line was fitted using the partial least square criterion (‘LOESS’) and illustrates the increase in accumulation rate with decreasing amyloid-β 42 levels as seen in CSF+/PET+ subjects and at lower amyloid-β 42 levels in CSF−/PET− subjects ( A ). The gap between CSF−/PET− and CSF+/PET− is caused by the exclusion of borderline cases. In B , the local regression line shows an accumulation rate that has plateaued and does not increase with decreasing CSF amyloid-β 42 levels.CC BY-NC · PubMed Central
Figure 4 Longitudinal changes in memory and hippocampal atrophy. ( A ) Illustration of the linear slopes in composite memory score for the three groups. The coefficients were calculated from scores at the ADNI baseline and the 12, 24, 36, 48 and 60-month visits. The CSF+/PET+ group deteriorated significantly in memory function, but no deterioration was seen in the other groups. The difference between CSF+/PET+ and the other groups was significant. ( B ) The coefficient of the hippocampal volume was calculated based on all available data at all ADNI visits. CSF+/PET+ progressed significantly more than the other groups. Supplementary Fig. 1A and B shows the individual trajectories of the composite memory score and the hippocampal volume.
Figure 4 Longitudinal changes in memory and hippocampal atrophy. ( A ) Illustration of the linear slopes in composite memory score for the three groups. The coefficients were calculated from scores at the ADNI baseline and the 12, 24, 36, 48 and 60-month visits. The CSF+/PET+ group deteriorated significantly in memory function, but no deterioration was seen in the other groups. The difference between CSF+/PET+ and the other groups was significant. ( B ) The coefficient of the hippocampal volume was calculated based on all available data at all ADNI visits. CSF+/PET+ progressed significantly more than the other groups. Supplementary Fig. 1A and B shows the individual trajectories of the composite memory score and the hippocampal volume.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 59 references

Research works printed but not linked: 1

  1. Biogen. A Randomized, Blinded, Placebo-Controlled Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of BIIB037 in Subjects with Mild to Moderate Alzheimer's Disease. In: AD/PD International Conference, Nice, France, 2015.

Cited by

Sorted by citations

Items 201–300 of 400

Related

See all

Metadata

Authors
Palmqvist, S., Mattsson, N., Hansson, O., & Initiative, F. T. A. D. N.
Affiliations
Lund University (SE)
Corresponding author
  • Palmqvist, Sebastian
  • Hansson, Oskar
ORCID
Venue
Brain
Publisher
Oxford University Press (OUP)
Published
2016-03-02
Volume
139
Issue
4
Pages
1226-1236
ISSN
  • 0006-8950 (ISSN-L)
  • 1460-2156
DOI
10.1093/brain/aww015
PMC
PMC4806222
OpenAlex
W2302528231
Cited by
400
References
59
Citations by year
2026: 32 · 2025: 41 · 2024: 33 · 2023: 31 · 2022: 36 · 2021: 58 · 2020: 50 · 2019: 43 · 2018: 38 · 2017: 25 · 2016: 11
FWCI
34.64
Type
journal article
Language
en
Open access
Licence
cc-by-nc
Locations
  • Brain (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Lund University Publications (Lund University) (submittedVersion)
  • HighWire Press Open Archive (submittedVersion)
Funders
  • Lunds Universitet
  • National Institutes of Health (5u01ag024904-10)
  • Canadian Institutes of Health Research
  • National Institute on Aging (U01-AG-024904)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Clinical Neurology › Cerebrospinal fluid and hydrocephalus
Keywords
cerebrospinal fluid amyloid-beta 42, amyloid PET, florbetapir, preclinical Alzheimer's disease, standardized uptake value ratio, memory decline, hippocampal volume, Alzheimer's dementia, biomarker comparison, ADNI cohort, longitudinal follow-up
MeSH terms
Aged, Aged, 80 and over, Alzheimer Disease, Cerebral Cortex, Cross-Sectional Studies, Female, Humans, Male, Middle Aged, Peptide Fragments, Prospective Studies, Amyloid beta-Peptides, Early Diagnosis, Positron-Emission Tomography

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review